Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present RXI Pharmaceuticals Corporation (OTC: RXII).

Full DD Report for RXII

You must become a subscriber to view this report.


Recent News from (OTC: RXII)

RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018
MARLBOROUGH, Mass. , Nov. 7, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, will present a...
Source: PR Newswire
Date: November, 07 2018 07:05
RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018
MARLBOROUGH, Mass. , Nov. 6, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced ...
Source: PR Newswire
Date: November, 06 2018 07:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-11-160.330.33020.3320.32460,683
2018-11-150.3150.330.3350.31939,743
2018-11-140.3830.33150.390.31012,923,533
2018-11-130.3390.3504280.360.339821,690
2018-11-120.410.350.41250.3334,798,274

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on RXII.


About RXI Pharmaceuticals Corporation (OTC: RXII)

Logo for RXI Pharmaceuticals Corporation (OTC: RXII)

RXi Pharmaceuticals Corporation OTCQX:RXII is a biotechnology company focused on discovering, developing, and commercializing innovative therapies based on its proprietary, next generation RNAi platform. Therapeutics that use RNA interference, or RNAi, have great promise because of their ability to silence or down regulate, the expression of a specific gene that may be expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi s first RNAi product candidate, RXI , entered into RXi s first human trial in . RXI targets connective tissue growth factor CTGF , a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.

 

Contact Information

 

 

Current Management

  • Geert Cauwenbergh / President, CEO
  • Tamara McGrillen / IR
  • Robert J. Bitterman / Chairman
  • Keith L. Brownlie /
  • Geert Cauwenbergh /
  • H. Paul Dorman /
  • Curtis Lockshin /

Current Share Structure

  • Market Cap: $10,142,462 - 03/21/2018
  • Issue and Outstanding: 2,369,734 - 01/08/2018

 


Recent Filings from (OTC: RXII)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 18 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 18 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 13 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 11 2018

 

 


Daily Technical Chart for (OTC: RXII)

Daily Technical Chart for (OTC: RXII)


Stay tuned for daily updates and more on (OTC: RXII)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RXII)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RXII is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RXII and does not buy, sell, or trade any shares of RXII. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/